Use of thiazolidinediones and risk of osteoporotic fracture: Disease or drugs?

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 5, 2012, Pages 507-514

  Bazelier, Marloes T ^a   Gallagher, Arlene M ^a,b   van Staa, Tjeerd Pieter ^a,b,c   Cooper, Cyrus ^c,d   Leufkens, Hubert G M ^a   Vestergaard, Peter ^e   de Vries, Frank ^a,c,f  

^a UTRECHT UNIVERSITY   (Netherlands)

^b MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adverse events; Fracture risk; Osteoporosis; Thiazolidinediones; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIGUANIDE; INSULIN; SULFONYLUREA;

ADULT; AGED; ANKLE FRACTURE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DISEASE DURATION; DISEASE SEVERITY; DRUG USE; FEMALE; FIBULA FRACTURE; FOLLOW UP; FOOT FRACTURE; FRAGILITY FRACTURE; HAND FRACTURE; HIP FRACTURE; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RADIUS FRACTURE; RISK FACTOR; TIBIA FRACTURE; ULNA FRACTURE; VERTEBRA FRACTURE; WRIST FRACTURE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; NETHERLANDS; OSTEOPOROTIC FRACTURES; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; THIAZOLIDINEDIONES; YOUNG ADULT;

EID: 84859971442     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3234     Document Type: Article

References (42)

1. Schernthaner G, Chilton RJ. Cardiovascular risk and thiazolidinediones-what do meta-analyses really tell us? Diabetes Obes Metab 2010; 12(12): 1023-1035.
2. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM, PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007; 49(17): 1772-1780.
3. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362(18): 1675-1685.
4. Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int 2008; 19(2): 129-137.
5. Benvenuti S, Cellai I, Luciani P, et al. Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells. J Endocrinol Invest 2007; 30(9): RC26-RC30.
6. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005; 146(3): 1226-1235.
7. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B. Bone is a target for the AD compound rosiglitazone. Endocrinology 2004; 145(1): 401-406.
8. Grey A, Bolland M, Gamble G, et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007; 92(4): 1305-1310.
9. Glintborg D, Andersen M, Hagen C, Heickendorff L, Hermann AP. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 2008; 93(5): 1696-1701.
10. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009; 180(1): 32-39.
11. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008; 168(8): 820-825.
12. Habib ZA, Havstad SL, Wells K, Divine G, Pladevall M, Williams LK. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010; 95(2): 592-600.
13. Douglas IJ, Evans SJ, Pocock S, Smeeth L. The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS Med 2009; 6(9): e1000154.
14. Solomon DH, Cadarette SM, Choudhry NK, Canning C, Levin R, Stürmer T. A cohort study of thiazolidinediones and fractures in older adults with diabetes. J Clin Endocrinol Metab 2009; 94(8): 2792-2798.
15. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007; 166(5): 495-505.
16. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos Int 2007; 18(4): 427-444.
17. Williams JP, Blair HC, McDonald JM, et al. Regulation of osteoclastic bone resorption by glucose. Biochem Biophys Res Commun 1997; 235(3): 646-651.
18. McNair P, Madsbad S, Christensen MS, et al. Bone mineral loss in insulin-treated diabetes mellitus: studies on pathogenesis. Acta Endocrinol (Copenh) 1979; 90(3): 463-472.
19. Bouillon R. Diabetic bone disease. Calcif Tissue Int 1991; 49(3): 155-160.
20. Yamagishi S, Nakamura K, Inoue H. Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients. Med Hypotheses 2005; 65(6): 1013-1015.
21. Nisbeth U, Lindh E, Ljunghall S, Backman U, Fellström B. Increased fracture rate in diabetes mellitus and females after renal transplantation. Transplantation 1999; 67(9): 1218-1222.
22. Rix M, Andreassen H, Eskildsen P. Impact of peripheral neuropathy on bone density in patients with type 1 diabetes. Diabetes Care 1999; 22(5): 827-831.
23. Vogt MT, Cauley JA, Kuller LH, Nevitt MC. Bone mineral density and blood flow to the lower extremities: the study of osteoporotic fractures. J Bone Miner Res 1997; 12(2): 283-289.
24. Hadjidakis D, Diamantopoulos E, Kokkinakis E, Sfakianakis M, Merakos G, Raptis SA. Bone mineral density in type II diabetics with macroangiopathy. J Bone Miner Res 1997; 12(Suppl 1): S516.
25. Herings RM. PHARMO: A Record Linkage System for Postmarketing Surveillance of Prescription Drugs in the Netherlands, in Department of Pharmacoepidemiology and Therapy. Utrecht University: Utrecht, 1993; p. 232.
26. Herings RM, Stricker BH, de Boer A, Bakker A, Sturmans F, Stergachis A. Current use of thiazide diuretics and prevention of femur fractures. J Clin Epidemiol 1996; 49(1): 115-119.
27. Pouwels S, Lalmohamed A, Leufkens B, et al. Risk of hip/femur fracture after stroke: a population-based case-control study. Stroke 2009; 40(10): 3281-3285.
28. van Staa TP, Wegman S, de Vries F, Leufkens B, Cooper C. Use of statins and risk of fractures. JAMA 2001; 285(14): 1850-1855.
29. De Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, Van Staa TP. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 2007; 56(1): 208-214.
30. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15(6): 993-1000.
31. Pouwels S, van Staa TP, Egberts AC, Leufkens HG, Cooper C, de Vries F. Antipsychotic use and the risk of hip/femur fracture: a population-based case-control study. Osteoporos Int 2009; 20(9): 1499-1506.
32. van den Brand MW, Samson MM, Pouwels S, et al. Use of anti-depressants and the risk of fracture of the hip or femur. Osteoporos Int 2009; 20(10): 1705-1713.
33. Herings RM, Stricker BH, de Boer A, Bakker A, Sturmans F. Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life. Arch Intern Med 1995; 155(16): 1801-1807.
34. Greenland S. Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology 1995; 6: 356-365.
35. Nguyen NT, Nguyen XM, Lane J, Wang P. Relationship between obesity and diabetes in a US adult population: findings from the National Health and Nutrition Examination Survey, 1999-2006. Obes Surg 2011; 21(3): 351-355.
36. Carnevale V, Romagnoli E, D'Erasmo E. Skeletal involvement in patients with diabetes mellitus. Diabetes Metab Res Rev 2004; 20(3): 196-204.
37. Christiansen C, Christensen MS, McNair P, Nielsen B, Madsbad S. Vitamin D metabolites in diabetic patients: decreased serum concentration of 24, 25-dihydroxyvitamin D. Scand J Clin Lab Invest 1982; 42(6): 487-491.
38. Inaba M, Nagasue K, Okuno S, et al. Impaired secretion of parathyroid hormone, but not refractoriness of osteoblast, is a major mechanism of low bone turnover in hemodialyzed patients with diabetes mellitus. Am J Kidney Dis 2002; 39(6): 1261-1269.
39. Botolin S, McCabe LR. Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways. J Cell Biochem 2006; 99(2): 411-424.
40. Mathiassen B, Nielsen S, Johansen JS, et al. Long-term bone loss in insulin-dependent diabetic patients with microvascular complications. J Diabet Complications 1990; 4(4): 145-149.
41. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008; 19(4): 385-397.
42. Thrailkill KM, Lumpkin CK Jr, Bunn RC, Kemp SF, Fowlkes JL. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol Endocrinol Metab 2005; 289(5): E735-E745.